Mr. Russell was most recently CEO of Corventis – a venture capital financed company that pioneered a wearable, wireless patch system for monitoring cardiac patients outside the hospital setting. During his tenure, Corventis gained four new FDA clearances, deployed the system commercially with patients in over 25 countries, and was acquired by Medtronic in 2014.
Mr. Russell has over 30 years of experience in the medical device field – including sales, marketing, business development and R&D. Immediately prior to Corventis he was head of US Sales for the Cardiac Rhythm Management (CRM) division of Boston Scientific, responsible for 1,300 employees and over $1.5 billion in revenue. Mr. Russell also served as General Manager for the LATITUDE Patient Management organization at Guidant / Boston Scientific where he led that team in deploying the industry’s first wireless in-home patient monitoring system to 80,000 patients.
Earlier in his career, Mr. Russell held the roles of sales representative, regional sales manager, and sales director, as well as manager of market planning and director of new product planning – all with Guidant’s CRM division. Prior to Guidant, Mr. Russell was a research and development engineer at Edwards Laboratories.
Mr. Russell holds a BS in mechanical engineering from Duke University and an MBA from the University of North Carolina, Chapel Hill.
Mr. Ballotta is currently Cardiva’s Chief Operating Officer. In this role, Mr. Ballotta is directly responsible for Engineering, Manufacturing Operations, Quality Assurance, Clinical and Regulatory Affairs, Customer Operations, and Information Technology. Mr. Ballotta joined Cardiva in June of 2010 as Vice President of Operations.
Prior to Cardiva, Mr. Ballotta had 13 years of experience across medical device design, development, manufacturing, marketing, and business assessments. Most recently, Mr. Ballotta worked at Johnson & Johnson subsidiary, Cordis Corporation, where he was responsible for new business assessments and strategic marketing for next generation structural heart and drug-eluting stents.
Prior to Mr. Ballotta’s business assessment and marketing roles, he held various leadership positions in Research & Development and Program Management. Ultimately, Mr. Ballotta was the General Manager for the Cardiovascular Technologies (CVT) business unit where he was responsible for global product development and commercialization in both the US (Miami) and in the EU (Netherlands), launching 8 PMA and 510(k) medical devices globally. Preceding this leadership role, Mr. Ballotta spent three years in the Netherlands leading research and development for coronary stent delivery systems and PTCA catheters. In 2000, Mr. Ballotta was a technical leader for the Checkmate System, the first brachytherapy device to utilize gamma radiation for the treatment of in-stent restenosis.
Mr. Ballotta co-founded Bio-Trainers, LLC; a company that focused on scanning technology of human cadavers for the development of surgical training tools, namely ACL and MCL repair.
Mr. Ballotta has a B.S. in Biomedical & Mechanical Engineering from the University of Miami, an M.S. in Engineering Management from Florida International University and an MBA from both Columbia Business School and the Haas School of Business at University of California Berkeley.
Ms. Garrett brings over 20 years of diversified finance experience to Cardiva, Inc. Most recently, Ms. Garrett had been the CFO and VP of Human Resources at Corventis, Inc, a wireless cardiac patient monitoring company that was acquired by Medtronic in 2014. Prior to Corventis, she was the Senior Director of Corporate Financial Planning and Analysis at Sybase. Ms. Garrett also spent seven years at Guidant Corporation, holding positions in Planning and Forecasting and Internal Audit while also leading a financial system implementation team. Prior to joining Guidant, Ms. Garrett worked at Eli Lilly and Company in a variety of financial roles, including Financial Planning and Corporate Treasury. Before entering the health care industry, she practiced as a CPA at Ernst and Young.
Ms. Garrett holds a BBS in Accounting, and an MBA from Indiana University.
Mr. Owens brings 21 years of experience in cardiology medical device sales to Cardiva Medical including Cardiac Rhythm Management, Electrophysiology, Coronary, Endovascular and Structural Heart. In his current role, he is responsible for all commercial operations and activities associated with Cardiva’s vascular closure device product line.
Most recently, Mr. Owens served on Senior Staff with Boston Scientific and Abbott Vascular where he was responsible for serving as Abbott Vascular’s key point of contact with senior level customers and stakeholders in large administrative and institutional health care organizations, and identifying novel commercial and healthcare economic solutions across the entire Abbott Vascular product portfolio. He was also responsible for developing and executing new strategic partnerships with internal divisions of Abbott and external companies.
Prior to this role, Mr. Owens served as a Director of Coronary and Endovascular Sales at Abbott Vascular. He also served as an Area Vice President of Cardiac Rhythm Management for Guidant Corporation/Boston Scientific and as the Vice President of US Sales for the Electrophysiology division of Boston Scientific.
Mr. Owens holds a Bachelor of Science in Biomedical Science, Bachelor of Arts in Psychology, and Masters of Science in Cardiac Physiology all from Ohio University.
Mr. Yassinzadeh joined Cardiva in March of 2003 as co-founder and Vice President of Research and Development. He has over 30 years of experience in design, development and manufacture of minimally invasive devices and their related instrumentation. Prior to joining Cardiva, he was at RITA Medical Systems as director of engineering, focused on their radiofrequency ablation technology. Prior to that, Mr. Yassinzadeh held management positions at Gynecare (acquired by Johnson & Johnson), Boehringer Mannheim, and Biotrack (acquired by CIBA-Corning). Mr. Yassinzadeh holds a BA in Physiology, a BS in Biomedical Engineering, and a MS degree in Electrical Engineering from Southern Illinois University. Mr. Yassinzadeh is the holder of over 35 issued or pending patents.
VASCADE® MVP receives FDA approval for 6-12F Inner Diameter (ID) multi-vessel venous vascular closure
Antegrade Study results published in Vascular Disease Management in 2018
VASCADE® receives FDA approval for use in femoral veins in 2018
VASCADE VCS approved by the FDA in 2013
VASCADE VCS approved for CE Mark in Europe in 2012
CATALYST III received 510(k) clearance in 2009
CATALYST II approved for CE Mark in Europe in 2008
CATALYST II received 510(k) clearance in 2007